Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis

Main Article Content

Leon Kircik
Mathew Zirwas
Shawn G. Kwatra
Michael Lewitt
Holly Glover
Tomas Chao
Philip M. Brown
David S. Rubenstein
Anna Tallman


Tapinarof, Aryl Hydrocarbon Receptor Agonist, Itch-free State, Itch, Pruritis, Plaque Psoriasis, Efficacy, PP-NRS, Topical


1. Amatya B, et al. J Eur Acad Dermatol Venereol. 2008;22:822–826.

2. Szepietowski JC, Reich A. Eur J Pain. 2016;20:41–46.

3. Yosipovitch G, et al. Br J Dermatol. 2000;143:969–973.

4. Komiya E, et al. Int J Mol Sci. 2020;21:8406.

5. Lebwohl MG, et al. Am J Clin Dermatol. 2016;17:87–97.

6. Dermavant Sciences. VTAMA (Tapinarof) Cream, 1%: US Prescribing Information. 2022. https://www.vtama.com/docs/DMVT_VTAMA_PI.pdf. Accessed October 2022.

7. Lebwohl MG, et al. N Engl J Med. 2021;385:2219–2229.

8. Yosipovitch G, et al. Br J Dermatol. 2019;181:761–769.

9. Finlay AY, Khan GK. Clin Exp Dermatol. 1994;19:210–216.

10. Lebwohl M, et al. Int J Dermatol. 2014;53:714–722.

11. Strober B, et al. J Am Acad Dermatol. 2022;87:800–806.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>